Pfizer Inc PFE has agreed to acquire Arena Pharmaceuticals Inc ARNA, a clinical-stage company developing therapies to treat several immuno-inflammatory diseases.
- Under the agreement terms, Pfizer will acquire Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion.
- Also See: Pfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See Highlights.
- Arena's portfolio includes development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator.
- Arena's etrasimod program includes two Phase 3 studies in ulcerative colitis (UC), a Phase 2/3 program in Crohn's Disease, a planned Phase 3 program in atopic dermatitis, and ongoing Phase 2 studies in eosinophilic esophagitis and alopecia areata.
- Pfizer expects to finance the transaction with existing cash on hand. It ended Q3 with cash and cash equivalents of $1.97 billion and short-term investments of $27.7 billion.
- Related: Arena Pharma In-Licenses Aristea's CXCR2 Antagonist For Immune-Mediated Inflammatory Diseases.
- Price Action: ARNA shares are up 93.00% at $96.39, and PFE stock is up 1.46% at $53.55 during the premarket session on Monday's last check.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.